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ABSTRACT
Some 90% of oral cancers consist of squamous cell carcinomas that arise from the oral mucosa. The remaining 10% 
of malignancies consist of malignant melanomas, carcinomas of the intraoral salivary glands, sarcomas of the soft tis-
sues and the bones, malignant odontogenic tumors, non-Hodgkin’s lymphomas and metastases from primary tumors 
located elsewhere in the body. These malignancies will be briefly reviewed and discussed. The emphasis is on diagnosis 
and management.
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INTRODUCTION
Malignancies of  the oral cavity largely (90%) consist of 
primary squamous cell carcinoma arising from the mu-
cosal lining. Tobacco and excessive use of  alcohol play 
an important role in the aetiology of these cancers. The 
remaining 10% of oral malignancies consist of a heteroge-
neous group of tumors of unknown aetiology, and comprise 
malignant melanoma, malignant intraoral salivary gland 
tumors, sarcomas of  the soft tissues and the jaw bones, 
non-Hodgkin’s lymphomas, and the rare oral metastases of 
primary tumors located elsewhere in the body. These oral 
non-squamous malignant tumors will be briefly discussed, 
the emphasis being on diagnosis and management.
ORAL MALIGNANT MELANOMA
Approximately 1% of all malignant melanomas arise in the 
oral mucosa. There are no known aetiologic factors. Oral 
pigmented nevi do not seem to be risk markers of future 
development of an oral malignant melanoma.The patients 
are usually above the age of 40 years. There is no distinct 
gender preference. The palate and the upper and lower 
gingival are the sites of preference (1).
The clinical presentation of  a malignant melanoma is 
usually a brown-black coloured swelling with or without 
ulceration (Fig. 1). Occasionally, there is no distinct melanin 
pigmentation, being referred to as an amelanotic melanoma. 
The diagnosis requires a biopsy. In case of suspicion of a 
cutaneous melanoma usually an excisional biopsy is re-
commended,  since it has been suggested that an incisional 
biopsy may enhance the risk of metastatic spread (2). In the 
oral cavity an excisional biopsy is often not feasible because 
of the presence of teeth or bones.
The histopathologic features can be misleading, particularly 
if  melanin pigment is not abundant. In such cases tumor 
markers such as HMB45 may be helpful to identity the 
nature of the tumor. 
There is a clinical staging system for head and neck ma-
lignant melanomas, including oral malignant melanomas, 
that recognizes three stages; furthermore, stage I can be 
subclassified in three levels (Table 1) (3).
Treatment usually consists of wide surgical excision. The 
role of postoperative radiotherapy is questionable. Adju-
vant chemotherapy does not seem to influence survival (4). 
Systemic immunotherapy with IL-2 and other cytokines is 
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not associated with an improved survival rate either (4). 
The detection of the so-called cancer testis antigens (CTAs) 
expression profile in oral malignant melanoma could lead 
to the development of  a new vaccine-based therapy (5). 
Prognosis is usually poor due to local recurrences and me-
tastatic spread, either through the lymph vessels or the blood 
stream. Clinical stage at presentation is probably the most 
important factor in determining outcome (6). In a study on 
230 patients surgically treated for roal malignant melanoma, 
thickness of  the tumor, cervical lymph node metastasis, 
presence or absence of ulceration and the anatomic sites 
were all independent risk factors (7).
Malignant melanoma is probably often preceded by diffuse 
areas of seemingly benign melanotic pigmentation, also re-
ferred to as melanosis. It is questionable whether treatment 
of melanosis is effective in preventing the development of 
a malignant melanoma.
TUMORS OF THE INTRAORAL SALIVARY 
GLANDS
Tumors of the intraoral salivary glands are relatively rare. 
The aetiology is unknown. The estimated incidence of be-
nign and malignant intraoral salivary gland tumors together 
is less than 1 per 100.000 population per year. The patients 
are usually above the age of 20 years. There is no distinct 
gender preference.
The posterior part of the palate is the site of predilection, 
followed by the upper lip. Occurrence of a salivary gland tu-
mor in the floor of the mouth is extremely rare. Interestingly, 
such salivary gland tumors in this location are nearly almost 
of a malignant type.  Intraoral salivary gland tumors rarely 
occur in the jaws. If  they do, it is usually the mandible.
The clinical presentation of both a benign and a malignant 
intraoral salivary gland tumors is often a slow growing, 
otherwise asymptomatic swelling with no characteristic 
features (Fig. 2). In other words, the nature of a salivary 
gland tumor, being benign or malignant, can not reliably 
be predicted on the clinical presentation alone. Usually 
preference is given to an incisional biopsy above fine nee-
dle aspiration cytology to arrive at a proper preoperative 
diagnosis. Only in well-circumscribed nodules in the lips or 
the cheek mucosa an excisional biopsy may be considered. 
Approximately 50% of all intraoral salivary gland tumors 
are malignant. One of the common malignant intraoral 
salivary gland tumors is the adenoid cystic carcinoma.
In 2005 the World Health Organisation has issued a revised 
histopathological classification (8). Histopathologic typing 
can at times be difficult, even more so in tumors of the minor 
salivary glands than in tumors of the major glands. There 
are several histopathological pitfalls, such as necrotising 
sialometaplasia and metastatic tumors that may mimic sali-
vary gland tumors. Tumor markers are in general of limited 
help in the histopathologic classification of salivary gland 
tumors. Grading of such tumors is of limited value with the 
possible exception of mucoepidermoid carcinomas.
Treatment consists of surgical removal and, on indication, 
of postoperative radiotherapy. Prognosis mainly depends 
on stage and histological type.
SARCOMAS OF THE ORAL SOFT TISSUES 
(EXCLUDING KAPOSI’S SARCOMA)
The estimated annual incidence of sarcomas of the oral soft 
tissue is approximately one per million population. They 
constitute less than one per cent of all oral malignancies. 
There are no known aetiologic factors. Soft tissue sarcomas 
may occur at all ages. There is no gender preference.
The clinical presentation is not characteristic and usua-
lly consists of a firm elastic swelling (Fig. 3). There is a 
wide variety of histological types, such as fibrosarcoma, 
liposarcoma, rhabdomyosarcoma. In 2002 a revised clas-
Stage I: Primary tumour present only (T any N0M0) 
 level I: Pure in situ melanoma without evidence of  
                                invasion or in situ melanoma with "microinvasion" 
 level II: Invasion up to the lamina propria 
 level III: Deep skeletal tissue invasion into skeletal muscle,  
                                  bone or cartilage 
Stage II: Tumour metastatic to regional lymph nodes (T any N1M0) 
Stage III: Tumour metastatic to distant sites (T any N any M1) 
Table 1. Clinical Staging System for OMM with histopathological mi-
crostaging for Stage I (3)
Fig. 1. Typical presentation of oral malignant melanoma. 
Note the surrounding areas of pigmentation.
Fig. 2. Slowly growing, otherwise asymptomatic salivary 
gland tumor of the palate. The biopsy showed the pres-
ence of a pleomorphic adenoma.
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sification of soft tissue tumors has been published by the 
WHO (9). Numerous types and subtypes have been iden-
tified in that classification. Many of these are difficult to 
classify histopathologically with certainty in spite of the 
use of tumor markers. Furthermore, some of these tumors 
are classified as intermediate tumors, between the category 
of benign and malignant ones, since metastases may occa-
sionally occur in such tumors, e.g. in solitary fibrous tumor 
and hemangiopericytoma. Histopathological grading, 
taking into account tumor differentiation, mitotic counts 
and tumor necrosis, evaluates the degree of  malignancy 
and the probability of distant metastases (9). In general, 
three groups are recognised, high, intermediate, and low 
grade malignancy. Staging, based on both clinical and 
histopathological parameters, provides information on the 
extent of tumor.
Treatment usually consists of wide surgical excision with 
or without (neo)adjuvant chemotherapy. In deeply located 
soft tissue sarcomas or in case of irradical removal of a soft 
tissue sarcoma, postoperative radiotherapy is often used, 
although no evidence-based data about the efficacy of such 
treatment is available. Prognosis mainly depends on stage 
and histological type (10, 11).
OSTEOSARCOMAS OF THE JAWS
Approximately 5% of all osteosarcomas that may occur 
in the skeleton arise in the jaws. Chondrosarcomas rarely 
affect the jaw bones. Osteosarcomas may affect children and 
young adults (12). There is no distinct gender preference. 
There are no known aetiologic factors other than the rare 
event of previous irradiation (13).
Clinical signs and symptoms may be inconspicuous, con-
sisting of  a low growing bony hard swelling of  the jaw 
bone. Mobility of teeth only occurs in a late stage. In case 
of  mandibular involvement the first sign of  malignany 
may be paraesthesia or anaesthesia of the ipsilateral site 
of the lower lip. The radiographic appearance may vary 
from diffuse radiolucent to densely opaque. Radiographic 
features suggestive of osteosarcoma are irregular widening 
of the periodontal ligament and loss of decortication of the 
follicular crypts of embedded teeth (Fig. 4).
Histopathologically, osteosarcoma may present in a 
wide range of  morphologic variations and may mimic, 
amongst others, fibro-osseous lesions, giant cell granuloma, 
cementoblastoma, and osteoblastoma. Conventional 
osteosarcoma is divided in three subtypes: 1) osteoblastic, 
2) chondroblastic, and 3) fibroblastic type (9).
Treatment consists of  (neo)adjuvant chemotherapy and 
surgery (14). There is hardly a role for postoperative radio-
therapy. If  radically excised, the prognosis of osteosarcoma 
of the jaws is rather favourable. If  metastases occur, the 
lungs are the most commonly affected organs.
NON-HODGKIN’S LYMPHOMA
The oral cavity may be the primary site of non-Hodgkin’s lym-
phoma. The estimated annual incidence is 1:1.000.000 popula-
tion. There is no gender preference. Non-Hodgkin’s lymphoma 
usually affects patients above their sixth decade.
There are no known aetiologic factors for non-Hodgkin’s 
lymphoma, except the rare event of an underlying human im-
munodeficiency virus infection. All sites of the oral cavity may 
be affected, but the palate seems to be a site of preference. The 
clinical presentation may vary considerably with involvement of 
either the soft tissues or the bone. Non-Hodgkin’s lymphomas 
are occasionally very fast growing tumors but they also may 
present in a rather indolent way (15). Ulceration of the overlying 
epithelium may or may not be present (Fig. 5).
Fig. 3. Fibrosarcoma of the gingiva and alveolar mucosa 
of 11 and 12. No bone involvement.
Fig. 4. Irregular widening of  the 
periodontal ligament of  11, sug-
gestive of osteosaroma.
Fig. 5. Non-Hodgkin’s lymphoma of  the palate pre-
senting as a slowly growing mucosal swelling. No bone 
involvement.
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Indolent lymphomas 
 B-cell neoplasms 
  Small lymphocytic lymphoma/B-cell chronic lymphocytic leukaemia 
  Lymphoplasmocytic lymphoma (± Waldenström's macroglobulinaemia) 
  Plasma cell myeloma/plasmacytoma 
  Hairy cell leukaemia 
  Follicular lymphoma (grades I and II) 
  Marginal zone B-cell lymphoma 
  Mantle cell lymphoma 
 T-cell neoplasms 
T-cell large granular lymphocytic leukaemia 
Mycosis fungoides 
T-cell prolymphocytic leukaemia 
 Natural killer cell neoplasms 
   Natural killer cell large granular lymphocytic leukaemia 
 Aggressive lymphomas 
  Follicular lymphoma (grade III) 
  Diffuse large B-cell lymphoma 
  Peripheral T-cell lymphoma 
  Anaplastic large cell lymphoma, T-null cell 
 Highly aggressive lymphomas 
  Burkitt lymphoma 
  Precursor B lymphoblastic leukaemia/lymphoma 
  Adult T-cell lymphoma/leukaemia 
  Precursor T lymphoblastic leukaemia/lymphoma 
 Special group of localized indolent lymphomas 
  Extranodal marginal zone B-cell lymphoma of MALT type* 
  Primary cutaneous anaplastic large cell lymphoma 
Stage Defining status 
Stage I* Restricted to single lymph node region (I) or a single extranodal site 
(I-E)
Stage II* Two or more areas of nodal involvement on same side of the 
diaphragm (II) or one or more lymph node regions with an extranodal 
site (II-E) 
Stage III* Lymphatic involvement on both sides of the diaphragm (III), 
possibly with an extranodal site (III-E), the spleen* (III-S), or both 
(III-SE)
Stage IV Liver, marrow, or other extensive extranodal disease 
Substage
Substage E Localised, extranodal disease 
Substage A Absence of systemic signs 
Substage B Presence of unexplained weight loss (  10% in 6 months), and/or 
unexplained fever, and/or night sweats 
Table 2. WHO REAL classification of non-Hodgkin lymphomas according to clinical 
aggressiveness (16).
* MALT = mucosa-associated lymphoid tissue
Table 3. Ann Arbor staging system (17).
* The spleen is considered nodal
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A biopsy is required to arrive at a proper diagnosis. Lym-
phoid tissue should be handled with care, since mechanic 
forces easily damage the cellular morphology, making the 
assessment of a reliable histopathological diagnosis difficult 
if  not impossible. Most of the oral non-Hodgkin’s lympho-
mas are of the B-cell type (Table 2) (16). Before treatment 
is instituted patients will be staged according to the Ann-
Arbor-system (Table 3) (17). In a group of 40 patients with 
an oral non-Hodgkin’s lymphoma, in whom the oral lesion 
was the presenting manifestation, 24 were staged as stage I, 
12 as stage IV and 1 and 2 as stage II and III, respectively 
(15). Treatment consists usually of  chemotherapy. The 
prognostic parameters are listed in table 4 (18).
ORAL METASTASES
Approximately 1% of all oral cancers consist of metastases 
derived from tumors located elsewhere in the body. In one-
third of the patients the oral lesion is diagnosed before the 
primary (19).
The primary is located in the common tumor sites, such 
as lung, breast, prostate and kidney. Oral metastases may 
either occur in the soft tissues or in the bone. In soft tissue 
involvement ulceration may or may not be present (Fig. 6)
Tumor markers may be of help in identifying the primary 
site. A well-known example is the use of prostate specific 
antigen in case of a metastasis of a prostate cancer.
In general, treatment possibilities of oral metastases are 
limited because of the often presence of multiple metas-
tases.
CONCLUSIONS
The oral non-squamous malignant tumors form a heteroge-
neous group of tumors of unknown aetiology. In contrast 
to oral squamous cell carcinoma these non-squamous cell 
oral cancers are not preventable. 
Probably due to their rare occurrence the signs and 
symptoms are often not recognized at an early stage. The 
histopathologic diagnosis may at times be difficult to esta-
blish with certainty. For the majority of these malignancies, 
non-Hodgkin’s lymphomas and oral metastases excepted, 
surgery is the treatment of choice, whereas the value of 
postoperative irradiation is questionable. Prognosis mainly 
depends on clinical stage and histopathologic type.
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